What are the recommended treatments for menstrual (premenstrual) migraine?

Treatment of Premenstrual/Menstrual Migraine

For acute treatment of menstrual migraine, start with a triptan combined with an NSAID, as this provides superior pain relief compared to monotherapy; for prevention, use short-term perimenstrual prophylaxis with frovatriptan 2.5 mg twice daily starting 2 days before expected menstruation.

Acute Treatment Approach

First-Line Therapy

• Initiate combination therapy with a triptan plus an NSAID as soon as the migraine begins, as menstrual migraines are typically more severe, longer-lasting, and less responsive to treatment than non-menstrual attacks 1.
• Sumatriptan and rizatriptan demonstrate the strongest evidence for acute treatment, with rizatriptan showing pain-free responses of 33-73% at 2 hours and sustained pain relief of 63% between 2-24 hours 2.
• Lasmiditan combined with sumatriptan provides superior pain relief at both 2 hours (OR: 4.62) and 24 hours (OR: 4.81) compared to other options 3.

Alternative Acute Options

• If NSAIDs are contraindicated, combine a triptan with acetaminophen 1.
• For mild menstrual migraine, consider starting with an NSAID alone (such as naproxen or mefenamic acid 500 mg) or acetaminophen before escalating 1, 4.
• Mefenamic acid 500 mg has specific evidence for menstrual migraine and addresses prostaglandin-mediated mechanisms 4.

Severe Presentations

• Use nonoral triptans with an antiemetic when severe nausea or vomiting is present 1.
• If combination therapy fails, consider CGRP antagonists (rimegepant, ubrogepant, or zavegepant) as second-line options 1.

Preventive Treatment Strategy

Short-Term Perimenstrual Prophylaxis

This is the preferred preventive approach for predictable menstrual migraines:

• Frovatriptan 2.5 mg twice daily has the strongest evidence for preventing headache recurrence when taken perimenstrually (starting 2 days before expected menstruation through day 3 of bleeding) 2, 4, 3.
• Naratriptan 1 mg twice daily is an alternative with grade B evidence for short-term prophylaxis 2, 4.
• Zolmitriptan 2.5 mg three times daily during the perimenstrual window also shows efficacy 2.
• Naproxen sodium 550 mg twice daily taken perimenstrually provides non-triptan prophylaxis 2, 4.

Hormonal Strategies

• Continuous combined hormonal contraceptives (CHCs) without placebo pills or using only 2 placebo days prevents estrogen withdrawal, the primary trigger for menstrual migraine 5.
• Transcutaneous estradiol 1.5 mg applied perimenstrually has grade B evidence for prevention 4.

Critical contraindication: Do NOT use CHCs in women with menstrual migraine WITH aura, as this represents an unacceptable health risk per U.S. Medical Eligibility Criteria for Contraceptive Use 2016 5.

Long-Term Daily Prevention

• If menstrual migraines occur frequently or short-term prophylaxis is inadequate, add daily preventive medications as per standard episodic migraine prevention guidelines 1.
• CGRP monoclonal antibodies (erenumab, galcanezumab) are more effective than triptans in reducing monthly headache days and show significant preventive benefits for menstrual migraine 3.
• Topiramate at doses below 200 mg/day has minimal effect on oral contraceptive efficacy if hormonal strategies are being used concurrently 2.

Critical Clinical Considerations

Medication Overuse Prevention

• Warn patients that triptans used ≥10 days per month can cause medication overuse headache 1.
• NSAIDs have a higher threshold of ≥15 days per month before causing medication overuse headache 1.
• Short-term perimenstrual prophylaxis (5-7 days per month) avoids this risk while providing effective prevention 6, 4.

Treatment Timing

• Counsel patients to begin acute treatment as soon as the migraine starts, not after it becomes severe, to improve efficacy 1.
• For predictable menstrual migraines, starting prophylaxis 2 days before expected menstruation is optimal 4.

Pregnancy and Lactation

• Discuss adverse effects of all pharmacologic treatments with women of childbearing potential before prescribing 1.
• Avoid triptans, NSAIDs (especially in third trimester), and hormonal therapies during pregnancy unless benefits clearly outweigh risks 1.

Pathophysiology-Based Selection

• Menstrual migraine results from estrogen withdrawal and prostaglandin release 5, 7.
• This explains why mefenamic acid (prostaglandin synthesis inhibitor) and estrogen supplementation have specific efficacy 5, 4.

Common Pitfalls to Avoid

• Do not use opioids or butalbital for menstrual migraine treatment, as these are explicitly contraindicated 1.
• Do not prescribe monotherapy when combination therapy is more effective; menstrual attacks are inherently more resistant to single-agent treatment 6, 7.
• Do not overlook the opportunity for short-term prophylaxis in women with predictable menstrual migraines, as this is often underutilized despite strong evidence 6, 4.
• Avoid enzyme-inducing antiepileptic drugs (except topiramate <200 mg/day) when using hormonal contraceptives for prevention, as they reduce contraceptive efficacy 2.